Search Results - Soto, Leofal

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

    Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers by Cantley, Jennifer, Ye, Xiaofen, Rousseau, Emma, Januario, Tom, Hamman, Brian D., Rose, Christopher M., Cheung, Tommy K., Hinkle, Trent, Soto, Leofal, Quinn, Connor, Harbin, Alicia, Bortolon, Elizabeth, Chen, Xin, Haskell, Roy, Lin, Eva, Yu, Shang-Fan, Del Rosario, Geoff, Chan, Emily, Dunlap, Debra, Koeppen, Hartmut, Martin, Scott, Merchant, Mark, Grimmer, Matt, Broccatelli, Fabio, Wang, Jing, Pizzano, Jennifer, Dragovich, Peter S., Berlin, Michael, Yauch, Robert L.

    Published in Nature communications
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

    Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast... by Gough, Sheryl M, Flanagan, John J, Teh, Jessica, Andreoli, Monica, Rousseau, Emma, Pannone, Melissa, Bookbinder, Mark, Willard, Ryan, Davenport, Kim, Bortolon, Elizabeth, Cadelina, Gregory, Gordon, Debbie, Pizzano, Jennifer, Macaluso, Jennifer, Soto, Leofal, Corradi, John, Digianantonio, Katherine, Drulyte, Ieva, Morgan, Alicia, Quinn, Connor, Békés, Miklós, Ferraro, Caterina, Chen, Xin, Wang, Gan, Dong, Hanqing, Wang, Jing, Langley, David R, Houston, John, Gedrich, Richard, Taylor, Ian C

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

    PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models by Berlin, Michael, Cantley, Jennifer, Bookbinder, Mark, Bortolon, Elizabeth, Broccatelli, Fabio, Cadelina, Greg, Chan, Emily W., Chen, Huifen, Chen, Xin, Cheng, Yunxing, Cheung, Tommy K., Davenport, Kim, DiNicola, Dean, Gordon, Debbie, Hamman, Brian D., Harbin, Alicia, Haskell, Roy, He, Mingtao, Hole, Alison J., Januario, Thomas, Kerry, Philip S., Koenig, Stefan G., Li, Limei, Merchant, Mark, Pérez-Dorado, Inmaculada, Pizzano, Jennifer, Quinn, Connor, Rose, Christopher M., Rousseau, Emma, Soto, Leofal, Staben, Leanna R., Sun, Hongming, Tian, Qingping, Wang, Jing, Wang, Weifeng, Ye, Crystal S., Ye, Xiaofen, Zhang, Penghong, Zhou, Yuhui, Yauch, Robert, Dragovich, Peter S.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Potent and Orally Bioavailable BCL6 PROTAC TM Degraders Demonstrate Efficacy in Pre-Clinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

    Potent and Orally Bioavailable BCL6 PROTAC TM Degraders Demonstrate Efficacy in Pre-Clinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) by Gough, Sheryl M, Sherman, Dan, DeCarr, Lynn, Eaton, Sarah, Milanovic, Maja, Bookbinder, Mark, Pizzano, Jennifer, Altieri, Martha, Corradi, John, Xiao, Hong, Gallego, Felipe, Soto, Leofal, Lingamaneni, Ram, Chen, Xin, Zhang, Wei, Wang, Gan, Dong, Hanqing, Chirnomas, Deborah, Berlin, Michael, Hornberger, Keith, Snyder, Lawrence, Taylor, Ian

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: